Concert Pharmaceuticals, Inc. (CNCE) saw a big move last session, as the company’s shares fell by over 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for CNCE, as the stock is now down over 4% in the past one-month time frame.
The medical company has seen a flat record when it comes to current year estimate revisions over the past few weeks (0 increases, 0 decreases), and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
CNCE currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Investors interested in the medical industry may consider better-ranked stock like Portola Pharmaceuticals, Inc. (PTLA), which carries a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment